Actively Recruiting
Phase 2 Study Evaluating Daily Oral D-2570 for Adults Aged 18-65 with Non-Segmental Vitiligo
Led by InventisBio Co., Ltd · Updated on 2026-07-15
160
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating D-2570, an investigational oral drug, for its safety and effect on skin discoloration in adults with non-segmental vitiligo. This Phase 2, randomized, double-blind, placebo-controlled study includes adults aged 18 to 65 with active or stable vitiligo, aiming to assess changes in skin pigmentation scores over time. Participants are randomly assigned to one of four groups receiving different doses of D-2570 or placebo once daily for 24 weeks. After this double-blind treatment period, some participants continue their assigned dose for another 24 weeks extension phase, while others are re-randomized to different doses, maintaining the blind. The study concludes with a 4-week safety follow-up after treatment ends. Throughout the study, participants attend regular visits for skin assessments, blood tests, safety monitoring, and pharmacokinetic evaluations. Measurements include facial and total vitiligo area scoring indexes to track skin changes, as well as quality of life questionnaires. The total study duration per participant is about 52 weeks, allowing close monitoring of treatment effects and safety.
CONDITIONS
Brief Title
Study of D-2570 in Subjects With Non-Segmental Vitiligo
Research Team
S
shilin Sha
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here